ROBO Medical’s Innovative Gastrointestinal Endoscopic Instrument Gains NMPA Approval
China’s National Medical Products Administration (NMPA) has approved ROBO Medical’s gastrointestinal endoscopic surgical instrument control...
Cancer
Akeso Biopharma’s Penpulimab Approved for First-Line NPC Treatment
China-based Akeso Biopharma (HKG: 9926) announced receiving another indication approval from the National Medical Products...
BioCity and MSD Enter Clinical Collaboration for BC3195 and Keytruda Combination Trial
China-based BioCity Biopharmaceutics Co., Ltd. announced a clinical collaboration agreement with US-based giant Merck, Sharp...
CSPC Pharmaceutical Group Receives FDA Approval for SYH2051 Clinical Trial
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced receiving approval from the US Food and...
Zai Lab Submits TIVDAK BLA to China’s NMPA for Cervical Cancer Treatment
Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) announced that a Biological License Application (BLA) for...
MindRank Ltd Receives FDA Clearance for MRANK-106 Clinical Study in Solid Tumors
China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd announced receiving clearance from the US Food...
AstraZeneca’s Imfinzi Approved by NMPA for Early-Stage NSCLC Treatment
UK-based giant AstraZeneca (NASDAQ: AZN) received approval from China’s National Medical Products Administration (NMPA) for...
Genmab’s HexaBody-CD38 Clinical Development Halted After J&J Opt-Out
Denmark-based Genmab A/S (NASDAQ: GMAB) announced that US giant Johnson & Johnson (J&J, NYSE: JNJ)...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-4602 Clinical Study in Advanced Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving approval from the National Medical...
Jiangsu Cowin Biotech Obtains NMPA License for Gene Methylation Detection Kit
China-based Jiangsu Cowin Biotech Co., Ltd. (SHA: 688426) announced receiving a Category III medical device...
Pfizer’s Elrexfio Receives Conditional NMPA Approval for Relapsed Multiple Myeloma
US giant Pfizer (NYSE: PFE) announced receiving conditional approval from China’s National Medical Products Administration...
TYK Medicines Inc.’s TY-9591 Shows Superiority Over Osimertinib in EGFR Mutated Lung Cancer with Brain Metastasis
Zhejiang-based TYK Medicines Inc. (HKG: 2410) announced positive results from a pivotal Phase II study...
Fosun Pharmaceutical’s Foritinib Accepted for Review by China’s NMPA for NSCLC Treatment
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that the National...
Abbisko Therapeutics’ ABSK131 Receives Clinical Trial Approval from China’s NMPA
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving clinical trial approval from...
Cryofocus Medtech’s Malignant Stenosis Cryoablation System Approved by NMPA for Chinese Market
Shanghai-based cryoablation treatment specialist Cryofocus Medtech (Shanghai) Co., Ltd (HKG: 6922) has announced receiving endorsement...
BioRay Biopharmaceutical’s BR111 Receives NMPA Clearance for Clinical Trials in ROR1-Positive Malignancies
Zhejiang-based BioRay Biopharmaceutical has announced receiving clearance from the National Medical Products Administration (NMPA) to...
Antengene’s Xpovio Receives Marketing Approval in Indonesia
China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced receiving marketing approval in Indonesia for its...
Yifan Pharma Secures Rights to Bayer’s Stivarga and Nexavar in China
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a commercialization agreement with Bayer (ETR: BAYN),...
RongCan Biotech’s mRNA HPV Vaccine Receives FDA Clinical Approval
China-based mRNA specialist RongCan (Shanghai) Biotech Co., Ltd announced that it has received clinical approval...
Baheal Pharmaceutical Gains Exclusive Rights to Roche’s MabThera in China
China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) last month reached an...